IHS Chemical Week

Markets :: Specialty Chemicals :: Electronic chemicals

Albemarle earnings fall on discontinued operations, but beat estimates

3:33 PM MDT | July 30, 2014 | Vincent Valk

Albemarle today reported second-quarter down 73% year-on-year (YOY), to $22.5 million, on sales up 5%, to $604.7 million. Net income fell due to an accounting loss on discontinued operations, namely the antioxidants, ibuprofen and propofol businesses Albemarle sold to SI Group during the quarter. Excluding this loss, and other, smaller, charges, adjusted earnings grew 10% YOY, to $86.8 million, or $1.10/share, ahead of analysts’ consensus estimate of $1.07/share, as reported by Thomson Reuters (New York). "Improved trends drove stronger than expected...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa